RFP
BCAX

Root Financial Partners’s Bicara Therapeutics BCAX Stock Holding History

Root Financial Partners’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-29
Closed -$577 – 3358
2026
Q1 		$577 Buy
+29
New +$499 ﹤0.01% 2819

Other funds holding BCAX

RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
NG
Norden Group Provo, Utah $1.22B AUM 36.64% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Root Financial Partners's BCAX Position: Q2 2026 in Review

Root Financial Partners sold out of Bicara Therapeutics (BCAX) in Q2 2026, closing a stake of 29 shares — an estimated $577 sold.

Root Financial Partners first reported a position in BCAX in Q1 2026 and held it in 1 quarter. The position peaked at $577 in Q1 2026. 20 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Root Financial Partners reported no remaining Bicara Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Root Financial Partners sold 29 Bicara Therapeutics shares in Q2 2026, an estimated $577.
  • Root Financial Partners first reported a position in Bicara Therapeutics in Q1 2026 and held it in 1 quarter.
  • Root Financial Partners's Bicara Therapeutics position peaked at $577 in Q1 2026.
  • 20 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Root Financial Partners's 13F filing for Q2 2026, filed 29 Jul 2026.